Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury shares) at CHF 44.31 per share, representing an equity value of approximately CHF 1.46 billion.

三星生物制剂将以每股44.31瑞士法郎的价格，发起一项全现金公开要约收购，收购PolyPeptide全部稀释后股本（不包括任何库存股）的100%，对应股权价值约为14.6亿瑞士法郎。

Strong transaction support, with a unanimous recommendation from PolyPeptide's Board members (acting through its independent and non-conflicted members) and an irrevocable tender undertaking from PolyPeptide's largest shareholder, representing approximately 55.65% of outstanding shares (excluding treasury shares)..

强有力的交易支持，包括来自PolyPeptide董事会成员（通过其独立且无利益冲突的成员行事）的一致推荐，以及来自PolyPeptide最大股东的不可撤销的投标承诺，该股东持有约55.65%的已发行股份（不包括库存股）。

PolyPeptide's specialized peptide expertise and global multi-site network to strengthen Samsung Biologics' multi-modality and global manufacturing excellence

PolyPeptide 在肽领域的专业专长及其全球多站点网络，将助力三星生物制剂强化其多模态能力与全球卓越制造水平

Strategic investment to propel Samsung Biologics' long-term growth strategy spanning portfolio, geography, and capacity

战略性投资以推动三星生物制剂在产品线、地域布局和产能方面的长期增长战略

INCHEON, South Korea

韩国仁川

,

，

July 19, 2026

2026年7月19日

/PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today announced the launch of an all-cash public tender offer to acquire 100% of the fully diluted share capital of PolyPeptide Group AG ('PolyPeptide') (ISIN CH1110760852, ticker symbol: PPGN), a leading global contract development and manufacturing organization (CDMO) specializing in peptide-based active pharmaceutical ingredients (APIs)..

/美通社/ -- 三星生物制剂（KRX: 207940.KS）今日宣布，发起一项全现金公开要约收购，以收购PolyPeptide Group AG（“PolyPeptide”）（国际证券识别码：CH1110760852，股票代码：PPGN）100%的完全稀释股本。PolyPeptide是一家全球领先的合同研发与生产组织（CDMO），专注于肽类活性药物成分（API）。

Continue Reading

继续阅读

Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India.

三星生物制剂宣布以全现金方式收购PolyPeptide，加速推进多模式战略，并扩大其在美国、欧洲和印度的全球网络。

Under the terms of the offer, PolyPeptide shareholders will receive CHF 44.31 in cash for each PolyPeptide share, representing an implied equity value of approximately CHF 1.46 billion. The transaction is expected to be completed towards the end of 2026, subject to customary offer conditions, including a minimum acceptance threshold of 66⅔%, applicable regulatory approvals, and other conditions described in the pre-announcement published today (.

根据要约条款，PolyPeptide 股东每持有一股 PolyPeptide 股份将获得 44.31 瑞士法郎的现金对价，对应的隐含股权价值约为 14.6 亿瑞士法郎。在满足惯例性要约条件（包括 66⅔% 的最低接受门槛、获得适用的监管批准以及今日发布的预公告中所述的其他条件）的前提下，预计该交易将于 2026 年底完成。

Link

链接

), and the offer prospectus to be published in accordance with Swiss takeover law.

），以及根据瑞士收购法将要发布的要约招股说明书。

After a comprehensive review of strategic options, PolyPeptide's Board of Directors, acting through its independent and non-conflicted members, unanimously recommend that PolyPeptide shareholders accept the tender offer, subject to the terms and conditions set forth in the offer prospectus. The Board determined that the transaction represents an attractive outcome for shareholders and PolyPeptide while positioning PolyPeptide for its next phase of growth as part of Samsung Biologics' global CDMO platform..

在对战略选项进行全面审查后，PolyPeptide董事会通过其独立且无利益冲突的成员一致建议PolyPeptide股东接受要约收购，但须遵守要约招股说明书中规定的条款和条件。董事会认为，该交易为股东和PolyPeptide带来了有吸引力的结果，同时使PolyPeptide作为三星生物制剂全球CDMO平台的一部分，为其下一阶段的增长做好准备。

With this transaction, Samsung Biologics will expand its capabilities beyond antibodies and ADCs to include peptide therapeutics, one of the fastest-growing segments of the biopharmaceutical industry, driven by surging global demand for obesity treatments and the continued expansion of peptide-based therapies into new disease areas.

通过此次交易，三星生物制剂公司将把其业务能力从抗体和抗体偶联药物（ADC）扩展至肽类治疗药物领域。在全球肥胖症治疗需求激增以及肽类疗法持续向新疾病领域拓展的推动下，肽类治疗药物已成为生物医药行业中增长最快的细分市场之一。

The transaction brings together Samsung Biologics' global manufacturing scale with PolyPeptide's specialized peptide expertise to create a differentiated, end-to-end multi-modality CDMO platform. PolyPeptide stands as one of the industry's top peptide CDMOs, distinguished by its advanced technology platform and proven track record, with more than 70 years of API manufacturing heritage and over 1,000 therapeutic peptides produced to date..

此次交易将三星生物制剂的全球制造规模与PolyPeptide在肽领域的专业专长相结合，打造一个具有差异化优势的端到端多模式CDMO平台。PolyPeptide是行业内领先的肽类CDMO之一，凭借其先进的技术平台和经证实的卓越业绩而脱颖而出，拥有超过70年的原料药制造传承，迄今已生产1,000多种治疗性肽。

PolyPeptide operates an integrated development-to-commercial model with growth focused on a modular, automation approach, giving it the flexibility to adapt quickly to changing market demand. Through PolyPeptide's peptide capabilities, innovative technologies, and proven commercial manufacturing track record, Samsung Biologics aims to serve clients across a broader range of therapeutic modalities by addressing growing demand for peptide-based therapeutics, particularly in obesity and diabetes, including .

PolyPeptide 采用从开发到商业化的集成模式，其增长战略侧重于模块化和自动化方法，从而使其能够灵活快速地适应不断变化的市场需求。借助 PolyPeptide 在多肽领域的专业能力、创新技术以及经证实的商业化生产业绩，三星生物制剂旨在通过满足对多肽类疗法（尤其是在肥胖和糖尿病领域）日益增长的需求，为更广泛治疗模式领域的客户提供服务。

GLP-1

GLP-1

therapies, while advancing innovation across high-growth areas such as oncology and other emerging indications.

疗法，同时在肿瘤学及其他新兴适应症等高增长领域推动创新。

The planned acquisition extends beyond adding capacity; it lays the foundation for Samsung Biologics' next phase of growth, supported by a strong pipeline of active peptide projects that includes a deep late-stage portfolio. PolyPeptide operates global sites across Sweden, Belgium, France, the United States, India, together with a corporate office in Switzerland and a separate Innovation Center in Strasbourg, France, with capabilities encompassing R&D, development, and commercial manufacturing..

此次计划中的收购不仅旨在增加产能，更为三星生物制剂的下一阶段增长奠定基础，其背后有强大的活性肽项目管线支持，其中包括深厚的后期阶段产品组合。PolyPeptide在瑞典、比利时、法国、美国和印度设有全球生产基地，并在瑞士设有公司总部，在法国斯特拉斯堡设有独立的创新中心，其能力涵盖研发、开发及商业化生产。

Upon completion of the transaction, Samsung Biologics will bring together PolyPeptide's highly experienced team and specialized peptide expertise, further enhancing its capabilities. By combining the companies' scientific strengths, manufacturing excellence, and global operations, the transaction is expected to enhance operational excellence, unlock additional growth opportunities, and further strengthen Samsung Biologics' position as a leading global multi-modality CDMO..

交易完成后，三星生物制剂将整合PolyPeptide经验丰富的团队和专业的多肽技术专长，进一步提升其能力。通过结合双方的科学优势、卓越制造能力和全球运营网络，此次交易有望提升运营卓越性，释放更多增长机会，并进一步巩固三星生物制剂作为全球领先的多模式合同研发生产组织（CDMO）的地位。

'This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including

“此次收购不仅通过将服务组合扩展至肽类等领域，还强化了我们的长期增长战略，包括

GLP-1

GLP-1

, but by also boosting our geographic reach and proximity further within the US, Europe, and India,' said John Rim, Chairman of the Board of Directors and CEO of Samsung Biologics. 'We highly value PolyPeptide's

“但同时也通过进一步扩大我们在美国、欧洲和印度的地理覆盖范围和贴近性，”三星生物制剂董事会主席兼首席执行官John Rim表示。“我们高度重视PolyPeptide的

world-class

世界级的

employees,

员工，

industry-leading

行业领先

capabilities, and global operational footprint, and look forward to leveraging the complementary strengths of PolyPeptide and Samsung Biologics in our continued growth supporting clients as the CDMO of choice for decades to come.'

能力以及全球运营布局，并期待借助PolyPeptide与三星生物制剂的互补优势，在未来数十年作为客户首选的CDMO合作伙伴，持续支持客户实现增长。

'PolyPeptide was built on the dedication of our employees, deep scientific expertise and strong customer focus. After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics' offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today,' said Peter Wilden, Chairman of the Board of Directors of PolyPeptide.

“PolyPeptide 的成就源于我们员工的奉献精神、深厚的科学专长以及对客户的高度重视。经过对战略选项的全面评估，董事会深信，三星生物制剂的报价为我们的股东提供了极具吸引力的方案，能够以诱人的现金价格带来即时且确定的价值。”PolyPeptide 董事会主席彼得·威尔登表示。

'At the same time, it represents a transformational opportunity to accelerate our strategic ambitions at a scale we could not reach alone – creating a stronger global partner for customers and a platform uniquely positioned to lead the next phase of growth in peptide-based therapeutics.'.

“与此同时，这也代表了一个变革性的机遇，能够以我们单独无法达到的规模加速实现我们的战略雄心——为客户打造更强大的全球合作伙伴，并建立一个独特定位的平台，引领基于肽的治疗药物的下一阶段增长。”

Samsung Biologics is launching an all-cash public tender offer for all publicly held shares in PolyPeptide. The Offer Price represents a 40% premium to the undisturbed share price of CHF 31.65 (the 'Unaffected Price'), being the last closing price of PolyPeptide's shares on the SIX Swiss Exchange ('SIX') as of 10 April 2026, which was the last trading day prior to the emergence of market rumors regarding a potential acquisition of PolyPeptide.

三星生物制剂正在发起一项全现金公开要约收购，旨在收购PolyPeptide所有公开发行的股份。要约价格较未受影响的股价31.65瑞士法郎（“未受影响价格”）溢价40%，该未受影响价格为PolyPeptide股份在瑞士证券交易所（“SIX”）于2026年4月10日的最后收盘价，而2026年4月10日是有关潜在收购PolyPeptide的市场谣言出现前的最后一个交易日。

The Offer Price represents an approximately 11.6% premium to the volume-weighted average share price over the last 60 trading days prior to the publication of this announcement. The Board of Directors of PolyPeptide, acting through its independent and non-conflicted members, unanimously recommends that shareholders accept the offer.

要约价格较本公告发布前最后60个交易日的成交量加权平均股价溢价约11.6%。PolyPeptide董事会通过其独立且无利益冲突的成员一致建议股东接受该要约。

The transaction is further supported by PolyPeptide's largest shareholder, who holds approximately 55.65% (based on total shares, excluding therefrom any treasury shares) and who has undertaken to tender all of its shares into the offer..

该交易还获得了PolyPeptide最大股东的支持，该股东持有约55.65%的股份（基于总股本，不包括任何库存股），并承诺将其持有的全部股份参与要约收购。

Indicative timeline

参考时间表

The offer by Samsung Biologics is conditioned upon at least two-thirds of all PolyPeptide shares on a fully diluted basis being tendered into the offer at the end of the offer period, together with other customary offer conditions, including the regulatory approvals set out in the pre-announcement.

三星生物制剂的要约以在要约期结束时，按完全稀释基础计算的PolyPeptide至少三分之二的股份已接受要约，以及其它常规要约条件（包括预公告中所述的监管批准）为条件。

The tender offer is expected to be launched by the end of August 2026 by publication of the formal offer prospectus and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange ('SIX'), following a ten trading-day cooling-off period under Swiss takeover law. The pre-announcement, published together with this press release, sets out the tender offer procedure and the specific terms and conditions of the offer..

预计要约收购将于2026年8月底前通过发布正式要约招股说明书启动，并在根据瑞士收购法规定的十个交易日冷静期之后，在瑞士六所交易所（“SIX”）保持开放至少二十个交易日。与本新闻稿一同发布的预公告详细说明了要约收购程序以及要约的具体条款和条件。

Once the offer has been successfully completed, Samsung Biologics intends to pursue a squeeze-out of any remaining minority shares and to delist PolyPeptide from the SIX, at which point PolyPeptide would become a wholly owned subsidiary of Samsung Biologics.

一旦要约成功完成，三星生物制剂计划对任何剩余的少数股东股份实施强制挤出，并将PolyPeptide从瑞士证券交易所（SIX）退市，届时PolyPeptide将成为三星生物制剂的全资子公司。

J.P. Morgan is acting as exclusive financial advisor to Samsung Biologics, with Ernst & Young Han Young serving as accounting and tax advisor. O'Melveny & Myers LLP and Schellenberg Wittmer Ltd are acting as legal advisors to Samsung Biologics.

摩根大通担任三星生物制剂的独家财务顾问，安永韩英会计师事务所担任会计及税务顾问。奥美律师事务所和谢伦伯格·威特默有限公司担任三星生物制剂的法律顾问。

About Samsung Biologics Co., Ltd.

关于三星生物制剂有限公司

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

三星生物制剂（KRX: 207940.KS）是一家领先的合同研发与生产组织（CDMO），提供从后期发现到商业化生产的一站式整合服务。

With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the acquisition of a manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities..

凭借位于韩国的第一和第二生物园区合计78.5万升的生物制造产能，以及通过收购美国马里兰州罗克维尔市一处生产设施获得的6万升产能，三星生物制剂的全球总制造产能达到84.5万升。此外，三星生物制剂已为第三生物园区预留土地，为未来扩大产能奠定基础，以支持下一代疗法和新兴治疗模式的发展。

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.

三星生物制剂利用尖端技术和专业知识，推进多种药物形式的发展，包括多特异性抗体、融合蛋白、抗体偶联药物和mRNA疗法。

By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

三星生物制剂通过在其制造网络中实施 ExellenS™ 框架，采用标准化设计、统一流程和先进数字化技术，确保工厂等效性和生产速度，以保障制造的连续性。

Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients.

三星生物制剂的全球制造和商业网络覆盖韩国、美国和日本。三星生物制剂美国公司服务于立足美国和欧洲的客户，而其东京销售办公室则服务于亚太地区。三星生物制剂持续投资新增能力，以最大化运营和质量卓越性，确保为客户带来灵活性和敏捷性。

Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit .

三星生物制剂致力于按时、足额交付安全且高质量的生物制药，并做出可持续的商业决策，以增进社会福祉和全球健康。如需更多信息，请访问。

https://samsungbiologics.com/

https://samsungbiologics.com/

.

。

Media Contacts

媒体联系人

Samsung Biologics

三星生物制剂

[Claire Kim /

[克莱尔·金 /

[email protected]

[email protected]

]

]

Investor Contacts

投资者联系方式

Samsung Biologics

三星生物制剂

[Jaewan Jun /

[全在焕 /

[email protected]

[email protected]

]

]

For additional information about the offer, please visit

如需了解优惠活动的更多信息，请访问

https://samsungbiologics.com/offer

https://samsungbiologics.com/offer

.

。

About PolyPeptide

关于PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries ('PolyPeptide') is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world.

PolyPeptide Group AG 及其合并子公司（“PolyPeptide”）是一家专注于肽类活性药物成分的合同开发与制造组织（CDMO）。通过主要支持制药和生物技术领域的客户，公司为全球数百万患者的健康做出贡献。

PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including .

PolyPeptide服务于一个快速增长的市场，提供从临床前到商业化阶段的产品和服务。其广泛的产品组合反映了跨领域药物疗法中的机遇，并在代谢疾病等领域具有显著的业务覆盖。

GLP-1

GLP-1

. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide's shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit

PolyPeptide 的历史可追溯至 1952 年，如今在全球运营着六家通过 GMP 认证的设施，分布於欧洲、美国和印度。PolyPeptide 的股票（SIX: PPGN）在瑞士 SIX 证券交易所上市。欲了解更多信息，请访问

polypeptide.com

多肽.com

.

。

Disclosure Notice

披露声明

The pre-announcement of the

预公告的

offer

提供

, which has been published today, is available at

，今日发布，可在以下网址获取：

https://samsungbiologics.com/offer

https://samsungbiologics.com/offer

.

。

The public tender

公开招标

offer

提供

is subject to customary terms and conditions as well as regulatory approvals and is currently expected to be completed by the end of 2026.

须遵守惯例条款和条件以及监管审批，目前预计将于2026年底前完成。

This publication does not constitute a prospectus or a similar notice according to articles 35 et seqq. and 69 of the Swiss Financial Services Act, is for information purposes only and does not constitute an offer document or an offer of securities for purchase or subscription, nor a solicitation of an offer to buy or subscribe for securities, in any jurisdiction.

本出版物不构成根据《瑞士金融服务法》第35条及后续条款和第69条规定的招股说明书或类似通知，仅供信息参考，并不构成在任何司法管辖区内的发售文件、购买或认购证券的要约，亦不构成征求购买或认购证券要约的行为。

The terms and conditions of the tender offer will be set out exclusively in the offer prospectus to be published in accordance with applicable Swiss takeover law, including the Swiss Financial Market Infrastructure Act and the Takeover Ordinance. Investors and holders of PolyPeptide shares are advised to carefully read the pre-announcement and the offer prospectus, as well as all other documents relating to the tender offer, once available, as they will contain important information about the offer.

要约收购的条款和条件将 exclusively 在根据适用的瑞士收购法律（包括《瑞士金融市场基础设施法》和《收购条例》）发布的要约招股说明书中载明。建议投资者及PolyPeptide股份的持有人仔细阅读预公告、要约招股说明书以及一旦发布的所有与要约收购相关的其他文件，因为这些文件将包含有关该要约的重要信息。

These documents will be made available in accordance with applicable law..

这些文件将根据适用法律提供。

Offer Restrictions

优惠限制

General

常规

The public tender offer for the registered shares with a nominal value of CHF 0.01 each (each a PolyPeptide Group Share) of PolyPeptide as described in the documents available on this website (the Offer) will not be made, directly or indirectly, in any country or jurisdiction in which it would be unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Biologics, Ltd., Incheon, Republic of Korea, (Samsung Biologics) or any of its direct and indirect subsidiaries launching the Offer, (the Offeror) to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer.

如本网站可得文件中所述，针对PolyPeptide每股面值为0.01瑞士法郎的注册股份（每股为“PolyPeptide集团股份”）的公开要约收购（“本次要约”）不会在任何国家或司法管辖区直接或间接进行，前提是该等行为在该等国家或司法管辖区属违法或以其他方式违反任何适用法律或法规，或会导致本次要约的发起方——位于大韩民国仁川的Samsung Biologics, Ltd.（“Samsung Biologics”）及其任何直接和间接子公司（统称“要约人”）——以任何方式变更或修改本次要约的条款或条件、向任何政府、监管或其他机构另行提交文件，或就本次要约采取其他额外行动。

It is not intended to extend the Offer to any such country or jurisdiction. Any document relating to the Offer must neither be distributed in any such country or jurisdiction nor be sent into such country or jurisdiction, and must not be used for the purpose of soliciting the purchase of securities of PolyPeptide by any person or entity resident or incorporated in any such country or jurisdiction.

本要约无意延伸至任何此类国家或司法管辖区。与要约相关的任何文件均不得在任何此类国家或司法管辖区内分发，也不得发送至此类国家或司法管辖区，且不得用于向居住于或在任何此类国家或司法管辖区内注册的任何个人或实体招揽购买PolyPeptide的证券。

Terms and conditions of the Offer have been and/or will be published in the Offer Documentation..

要约的条款和条件已在及/或将在要约文件中公布。

United States of America

美利坚合众国

The Offer will be made in the U.S. pursuant to Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the U.S. Exchange Act), subject to the exemptions provided by Rule 14d-1(c) under the U.S. Exchange Act (the Tier I Exemption) and Rule 14e-5(b)(10) under the U.S.

本次要约将依据经修订的《1934年美国证券交易法》（以下简称“美国《交易法》”）第14(e)条及其下的14E条例在美国进行，但须遵守美国《交易法》下规则14d-1(c)（即“第一层级豁免”）和规则14e-5(b)(10)所规定的豁免。

Exchange Act and any exemptions that may be granted by the U.S. Securities and Exchange Commission (SEC), and otherwise in accordance with the requirements of Swiss law. Accordingly, the Offer will be subject to disclosure and other procedural requirements, including with respect to withdrawal rights, settlement procedures and timing of payments that are different from those applicable under U.S.

《交易法》以及美国证券交易委员会（SEC）可能授予的任何豁免，并 otherwise 符合瑞士法律的要求。因此，本次要约将受披露及其他程序性要求的约束，包括关于撤回权、结算程序和付款时间的规定，这些规定与美国适用的规定不同。

domestic tender offer procedures and laws..

国内要约收购程序及法律

Any financial statements or figures included or referenced in the offer prospectus have been or will be prepared in accordance with the applicable accounting standards of, or recognized in, Switzerland and/or the Republic of Korea, which may not be comparable to the financial statements of U.S. companies..

招股说明书中包含或提及的任何财务报表或数据，均已或将根据瑞士和/或大韩民国适用或认可的会计准则编制，这些财务报表或数据可能无法与美国公司的财务报表相媲美。

In accordance with the laws of Switzerland and subject to applicable regulatory requirements, Samsung Biologics and its subsidiaries (including the Offeror) and affiliates or their respective nominees or brokers (acting as agents for the Offeror) may from time to time after the date of the offer prospectus, and other than pursuant to the Offer, directly or indirectly, purchase or arrange to purchase PolyPeptide Group Shares or any securities that are convertible into, exchangeable for or exercisable for PolyPeptide Group Shares from their holders who are willing to sell them outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, and shall comply with applicable laws and regulations in Switzerland and applicable U.S.

根据瑞士法律并受适用监管要求的约束，三星生物制剂及其子公司（包括要约人）和关联公司或其各自的被提名人或经纪人（作为要约人的代理人）可能在要约招股说明书日期之后不时地，在要约之外，直接或间接地从愿意在要约之外出售的持有人处购买或安排购买PolyPeptide集团股份或任何可转换为、交换为或可行使为PolyPeptide集团股份的证券，包括以现行价格在公开市场购买或以协商价格在私人交易中购买，并应遵守瑞士适用的法律法规以及美国适用的法律法规。

securities laws, rules and regulations, including Rule 14e-5 under the U..

证券法律、规则和条例，包括美国《1934年证券交易法》第14e-5条规则

S.

S.

Exchange Act (subject to the exemptions provided by Rule 14e-5(b)(10) under the U.S. Exchange Act). Any such purchases will not be made at prices higher than the offer price or on terms financially more favorable than those offered pursuant to the Offer, unless the offer price is increased accordingly.

《交易法》（但须遵守美国《交易法》下第14e-5(b)(10)条规定的豁免）。任何此类购买不得以高于要约价格或在财务条款上优于根据本次要约所提出条款的价格进行，除非要约价格相应提高。

Any information about such purchases or arrangements to purchase will be publicly disclosed in the U.S. on .

有关此类购买或购买安排的任何信息将在美国公开披露。

offer website

优惠网站

if and to the extent that such information is made public in accordance with the applicable laws and regulations of Switzerland. In addition, the financial advisor to PolyPeptide and, subject to applicable Swiss and U.S. securities laws, rules and regulations, including Rule 14e-5 under the U.

如果且仅在此类信息根据瑞士适用的法律法规被公开的情况下。此外，PolyPeptide 的财务顾问，在遵守适用的瑞士和美国证券法律、规则和条例（包括美国《1934年证券交易法》下的第14e-5条）的前提下，

S.

S.

Exchange Act (subject to the exemptions provided by Rule 14e-5(b)(10) under the U.S. Exchange Act), the financial advisor to Samsung Biologics and its subsidiaries (including the Offeror) and affiliates may also engage in ordinary course trading activities in securities of PolyPeptide, which may include purchases or arrangements to purchase such securities..

《交易法》（受限于美国《交易法》下第14e-5(b)(10)条规定的豁免），三星生物制剂及其子公司（包括要约人）和关联方的财务顾问也可能参与PolyPeptide证券的常规交易活动，其中包括购买或安排购买此类证券。

It may be difficult for holders of Company Shares in the U.S. (U.S. Holders) to enforce their rights and any claim they may have arising out of U.S. securities laws, since the Offeror and PolyPeptide are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S.

由于要约人和PolyPeptide均位于美国境外司法管辖区，且其部分或全部高级管理人员和董事可能为非美国居民，因此美国的公司股份持有人（“美国持有人”）可能难以执行其权利以及依据美国证券法产生的任何索赔。

jurisdiction. U.S. Holders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment..

管辖权。美国持有人可能无法在美国或外国的法院就违反美国证券法的行为对非美国公司或其高级管理人员或董事提起诉讼。此外，可能难以强制非美国公司及其关联公司服从美国法院的判决。

The receipt of cash pursuant to the Offer by a U.S. Holder may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. Each shareholder of PolyPeptide is urged to consult his or her independent professional advisor immediately regarding the tax consequences of an acceptance of the Offer..

美国持有人根据要约收取现金的行为，就美国联邦所得税目的以及适用的美国州和地方法律、外国及其他税法而言，可能构成应税交易。敦促PolyPeptide的每位股东立即就接受要约的税务后果咨询其独立专业顾问。

Neither the SEC nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer; (b) passed upon the merits or fairness of the Offer; or (c) passed upon the adequacy or accuracy of the disclosure in this Pre-Announcement. Any representation to the contrary is a criminal offence in the U.S..

美国证券交易委员会（SEC）及美国任何州的证券委员会均未：(a) 批准或不批准本次要约；(b) 对本次要约的优点或公平性作出评判；或 (c) 对本预公告中披露信息的充分性或准确性作出评判。任何与此相反的陈述均构成美国的刑事犯罪。

U.S. Holders are encouraged to consult with their own legal (including with respect to Swiss law), financial and tax advisors regarding the Offer.

鼓励美国持有人就本次要约咨询其各自的法律（包括涉及瑞士法律方面）、财务及税务顾问。

United Kingdom

英国

The communication about this Offer is not being made by, and has not been approved by, an authorised person for the purposes of Section 21 of the Financial Services and Markets Act 2000, as amended. In the United Kingdom (U.K.), this communication and any other documents relating to the Offer is/will be directed only at persons (i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the Order), (ii) falling within article 49(2)(a) to (d) ('high net worth companies, unincorporated associations, etc.') of the Order or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as 'relevant persons').

关于本次要约的沟通并非由经授权人士作出，亦未经其批准，该等人士系就《2000年金融服务与市场法》（经修订）第21条之目的而言。在英国（U.K.），本沟通及与本次要约相关的任何其他文件仅面向以下人士：(i) 在涉及属于《2000年金融服务与市场法（金融促销）令2005》（经修订，下称“该令”）第19(5)条范围内的投资事项方面具有专业经验的人士；(ii) 符合该令第49(2)(a)至(d)条（“高净值公司、非法人团体等”）规定的人士；或(iii) 其他可依法向其传达该等信息的人士（所有此类人士合称为“相关人士”）。

No communication in respect of the Offer must be acted on or relied on in the U.K. by persons who are not relevant persons. The Offer and any investment or investment activity to which this communication relates is / will be available in the U.K. to relevant persons only and will be engaged in only with relevant persons..

非相关人士不得在英国依据或依赖与本次要约相关的任何沟通行事。本次要约以及本沟通所涉及的任何投资或投资活动，仅向相关人士提供，并且仅与相关人士进行。

Australia, Canada and Japan

澳大利亚、加拿大和日本

The Offer will not be addressed to shareholders of PolyPeptide whose place of residence, seat or habitual abode is in Australia, Canada, or Japan, and such shareholders may not accept the Offer.

本要约不向住所、注册地或惯常居所在澳大利亚、加拿大或日本的PolyPeptide股东发出，该等股东亦不得接受本要约。

Forward Looking Statements

前瞻性陈述

This announcement contains forward-looking statements that reflect Samsung Biologics' current expectations and views of future events. These statements can often be identified by terms such as 'expect,' 'intend,' 'plan,' 'anticipate,' 'target,' 'believe,' 'will' and similar expressions. They include, among other things, statements relating to the expected timing, structure and completion of the tender offer; the anticipated benefits and synergies of the proposed transaction; and the future business, operations, financial performance and strategy of Samsung Biologics and PolyPeptide..

本公告包含前瞻性陈述，反映了三星生物制剂公司对未来事件的当前预期和观点。这些陈述通常可通过“期望”、“打算”、“计划”、“预见”、“目标”、“相信”、“将”等词语及类似表述来识别。其中包括（但不限于）与要约收购的预期时间安排、结构和完成相关的陈述；拟议交易预期的益处和协同效应；以及三星生物制剂公司和PolyPeptide未来的业务、运营、财务表现和战略。

These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond Samsung Biologics' control, that could cause actual results to differ materially from those expressed or implied. Such factors include, among others, the satisfaction of the conditions to the tender offer, the receipt of required regulatory approvals, the level of acceptance of the offer by PolyPeptide shareholders, the ability to successfully integrate PolyPeptide's business, developments in the peptide and broader CDMO markets, and general economic and market conditions.

这些前瞻性陈述受多种风险和不确定性的影响，其中许多超出三星生物制剂的控制范围，可能导致实际结果与明示或暗示的结果存在重大差异。此类因素包括但不限于：要约收购条件的满足、获得必要的监管批准、PolyPeptide 股东对要约的接受程度、成功整合 PolyPeptide 业务的能力、肽类市场及更广泛的合同研发生产组织（CDMO）市场的发展，以及总体经济和市场状况。

No assurance can be given that the transactions described herein will be completed or as to the final terms..

无法保证本文所述的交易将完成，也无法保证其最终条款。

Forward-looking statements speak only as of the date of this announcement and are based on information currently available to Samsung Biologics. Except as required by applicable law, Samsung Biologics undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise..

前瞻性陈述仅反映本公告发布之日的情况，并基于三星生物制剂目前可获得的信息。除适用法律要求外，三星生物制剂不承担公开更新或修订任何前瞻性陈述的义务，无论该等更新或修订是由于新信息、未来事件或其他原因所致。

SOURCE Samsung Biologics

来源：三星生物制剂

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量与

Request a Demo

申请演示